ReviewLipids in health and disease2026
Mechanistic insights and ameliorative strategies: advances in DEHP-induced metabolic toxicity and intervention by natural bioactive compounds and probiotics.
Review in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhanced hepatoprotective effects of fisetin-loaded liposomal nanoparticles against DEHP-induced liver injury in rats: modulation of oxidative stress, inflammation, apoptosis, and ferroptosis pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Di-(2-ethylhexyl) phthalate (DEHP) is a ubiquitous plasticizer and environmental contaminant linked to severe metabolic disorders. This review concisely elucidates the multi-organ mechanisms of DEHP-induced toxicity, highlighting its disruption of lipid, glucose, and protein homeostasis. Specifically, we delineate the crucial crosstalk between oxidative stress, endoplasmic reticulum (ER) stress, and inflammatory pathways that drive DEHP pathobiology. Furthermore, we systematically evaluate emerging ameliorative strategies, focusing on natural bioactive compounds and probiotics. We highlight how these interventions mitigate DEHP toxicity by targeting specific molecular hubs (e.g., PPARs, Nrf2) and restoring gut microbiota balance. By integrating mechanistic insights with natural interventions, this review provides a targeted framework for developing therapeutic countermeasures against phthalate-induced metabolic disruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.